The Cooper Companies(US:COO) Globenewswire·2025-12-23 13:00Core Viewpoint - CooperCompanies has appointed Walter (Walt) M Rosebrough, Jr. as an independent director and entered into a cooperation agreement with Browning West, aiming to enhance governance and drive long-term value for shareholders [1][3]. Group 1: Appointment and Governance - Walter Rosebrough will join the Board's Corporate Governance & Nominating Committee and is being considered for the Chair position by the end of 2026 [1]. - The Board will also appoint a new independent director with medical technology experience, in agreement with Browning West [1]. Group 2: Background of Walter Rosebrough - Rosebrough served as CEO of STERIS from 2007 to 2021, achieving a 10-fold total return on stock and an 18% annualized return, compared to a 10% annualized return for the S&P 500 [2]. - His career includes nearly two decades at Hill-Rom Holdings, where he held senior executive roles [2]. Group 3: Strategic Vision and Cooperation - Colleen Jay, the Incoming Chair of the Board, emphasized Rosebrough's leadership experience and track record in supporting sustainable growth [3]. - Browning West expressed confidence in Cooper's long-term potential and the constructive path forward with the Board [3]. - Browning West has agreed to customary standstill and voting commitments and will support the Board's full slate of directors at the 2026 Annual Meeting [3]. Group 4: Company Overview - CooperCompanies is a global medical device company with two business units: CooperVision and CooperSurgical, impacting over fifty million lives annually [4]. - The company is headquartered in San Ramon, CA, employs over 15,000 people, and sells products in over 130 countries [4]. Group 5: About Browning West - Browning West is an independent investment partnership focused on long-term value creation in high-quality businesses, primarily in North America and Western Europe [5]. - Founded in 2019, it is backed by leading foundations, family offices, and university endowments [5].